1. News & Events
  2. Blog

Blog

Vanderbilt licensee CN Bio Innovations announces research collaboration with AstraZeneca

Organ-on-a-Chip specialist CN Bio Innovations Limited announces a research collaboration with global biopharmaceutical company AstraZeneca to validate a new in vitro research tool that enables the high throughput evaluation of multi-drug dosing regimens.

CN Bio Innovations, a Vanderbilt licensee, and FDA sign collaborative agreement using Organ-on-Chip technologies

CN Bio Innovations Limited announces that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research.

CN Bio Innovations announces licence of platform microfluidics technologies from Vanderbilt University

CN Bio Innovations Limited announces that it has licensed from Vanderbilt University three patents and applications, and software, covering microfluidics technologies relevant to the company’s Organs-on-Chips products and IP portfolio.

The agreement includes exclusive rights to applications claiming priority from US 15/191,092, as well as non-exclusive rights to US 9,618,129 and applications claiming priority from US 13/877,925. 

Breast Cancer Innovation Month

Breast Cancer Innovation Month

Four Vanderbilt technologies earn patent protection

Four new Vanderbilt technologies earn patent protection in September.

 

Vanderbilt and Bayer collaborate to develop new therapies against kidney diseases

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.

Ten Vanderbilt technologies earn patent protection

Ten new Vanderbilt technologies earn patent protection in August.

9,747,490     Cell size imaging

Vanderbilt begins phase 1 trials of new Alzheimer’s drug

A potential new drug for Alzheimer’s disease and schizophrenia developed by Vanderbilt University scientists was administered July 29 to the first volunteer enrolled in a first-in-human phase 1 clinical trial at the Vanderbilt Institute for Clinical and Translational Research.

Animal studies suggest that the compound, a small molecule called VU319, may have potential for reducing memory impairments in brain disorders such as Alzheimer’s disease and schizophrenia.

Vanderbilt Professor John Wikswo and group selected for 2017 R&D100 Awards

A technology developed by Vanderbilt Professor John Wikswo and his group has been selected as a Finalist for the 2017 R&D100 Awards. The award honors 100 top innovations of the prior year, as selected by a panel of expert judges, and is in its 55th year of recognizing great R&D pioneers and their revolutionary technologies.

Vanderbilt technologies earn patent protection

Four new Vanderbilt technologies earned patent protection in July.

9,708,278            Substituted 4-benzyl-3,4-dihydro-2H-benzo[B][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1